ウイルスベクターおよびプラスミドDNA：各種技術および世界市場

世界のウイルスベクターおよびプラスミドDNAの市場規模は、2023年の29億米ドルから、予測期間中は19.7%のCAGRで推移し、2028年末には71億米ドルの規模に成長すると予測されています。

ウイルスベクター技術の市場は2023年の18億米ドルから、同期間中20.7%のCAGRで推移し、2028年末には45億米ドルの規模に成長すると予測されています。また、プラスミドDNA技術の市場は2023年の11億米ドルから、17.9%のCAGRで推移し、2028年末には26億米ドルの規模に成長すると予測されています。

当レポートでは、世界のウイルスベクターおよびプラスミドDNAの市場を調査し、市場概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、臨床試験・特許の動向、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場見通し
• 調査範囲
• 市場サマリー

第2章 市場概要

• ウイルス技術
• 細胞および遺伝子治療

第3章 市場力学

• 市場力学
• 促進要因
• 機会
• 抑制要因
• 課題

第4章 新興技術と開発

• 概要
• ウイルスベクター生産におけるAI
• ドギーボーンDNA
• FRAGment Recycler：プラスミドDNA合成の新技術
• 特許
• メーカー別の特許保有状況
• 臨床試験
• ウイルスベクターとプラスミドDNA技術の臨床試験

第5章 世界のウイルスベクターおよびプラスミドDNA技術市場

• 分類
• 市場内訳：製品タイプ別
• 市場内訳：エンドユーザー別
• 研究機関
• 製薬・バイオ医薬品企業
• 市場内訳：用途別
• 癌
• 遺伝性疾患
• 感染症
• 心血管疾患
• その他の病気
• 地理的内訳
• 市場内訳：地域別
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• その他の地域

第6章 競合情報

• 業界シナリオ
• 企業シェア
• 企業間の競合情勢
• 競合情勢：ウイルスベクター
• 競合情勢：プラスミドDNA

第7章 ウイルスベクターおよびプラスミドDNA技術市場における持続可能性：ESGの観点

• 環境要因
• 社会要因
• ガバナンス要因
• 主要企業のESGパフォーマンス
• 主要企業のESGパフォーマンス
• Lonza：ESGパフォーマンス
• Thermo Fisher Scientific：ESGパフォーマンス
• 総論

第8章 付録

• 調査手法
• 頭字語
• 参考文献
• 企業プロファイル
• AGILENT TECHNOLOGIES INC.
• BLUEBIRD BIO INC.
• CATALENT INC.
• DANAHER CORP.
• FUJIFILM HOLDINGS CORP.
• GENSCRIPT
• GILEAD SCIENCES INC.
• LONZA
• NOVARTIS AG
• OXFORD BIOMEDICA PLC
• PLASMIDFACTORY GMBH
• REGENXBIO INC.
• THERMO FISHER SCIENTIFIC INC.
• VGXI INC.

List of Tables

• Summary Table : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
• Table 1 : Global Incidence of All Cancers, by WHO Region, 2022-2050
• Table 2 : Global Incidence of Leukemia, by WHO Region, 2022-2050
• Table 3 : Global Incidence of Hodgkin Lymphoma, by WHO Region, 2022-2050
• Table 4 : Global Incidence of Non-Hodgkin Lymphoma, by WHO Region, 2022-2050
• Table 5 : Global Incidence of Multiple Myeloma, by WHO Region, 2022-2050
• Table 6 : Patents Held by Oxford Biomedica, 2021-Present
• Table 7 : Selected Patents Held by Lonza, 2021-Present
• Table 8 : Patents Held by Regenxbio, 2021-Present
• Table 9 : Selected Clinical Trials, by Viral Vector Type
• Table 10 : Global Market for Viral Vector and Plasmid DNA Technologies, Through 2028
• Table 11 : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
• Table 12 : Global Market for Plasmid DNA Technology, by Region, Through 2028
• Table 13 : Global Market for Viral Vector Technology, by Region, Through 2028
• Table 14 : Global Market for Viral Vector and Plasmid DNA Technologies, by End User, Through 2028
• Table 15 : Global Market for Viral Vector and Plasmid DNA Technologies in Research Institutes, Through 2028
• Table 16 : Global Market for Viral Vector and Plasmid DNA Technologies in Research Institutes, by Region, Through 2028
• Table 17 : Global Market for Viral Vector and Plasmid DNA Technologies in Pharmaceutical and Biopharmaceutical Companies, Through 2028
• Table 18 : Global Market for Viral Vector and Plasmid DNA Technologies in Pharmaceutical and Biopharmaceutical Companies, by Region, Through 2028
• Table 19 : Global Market for Viral Vector and Plasmid DNA Technologies, by Application, Through 2028
• Table 20 : Global Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
• Table 21 : Global Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Region, Through 2028
• Table 22 : North American Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
• Table 23 : North American Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
• Table 24 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
• Table 25 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
• Table 26 : European Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
• Table 27 : European Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
• Table 28 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
• Table 29 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
• Table 30 : RoW Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
• Table 31 : Global Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
• Table 32 : Global Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Region, Through 2028
• Table 33 : North American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
• Table 34 : North American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
• Table 35 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
• Table 36 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
• Table 37 : European Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
• Table 38 : European Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
• Table 39 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
• Table 40 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
• Table 41 : RoW Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
• Table 42 : Global Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
• Table 43 : Global Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Region, Through 2028
• Table 44 : North American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
• Table 45 : North American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
• Table 46 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
• Table 47 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
• Table 48 : European Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
• Table 49 : European Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
• Table 50 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
• Table 51 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
• Table 52 : RoW Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
• Table 53 : Global Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
• Table 54 : Global Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Region, Through 2028
• Table 55 : North American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
• Table 56 : North American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
• Table 57 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
• Table 58 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
• Table 59 : European Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
• Table 60 : European Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
• Table 61 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
• Table 62 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
• Table 63 : RoW Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
• Table 64 : Global Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
• Table 65 : Global Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Region, Through 2028
• Table 66 : North American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
• Table 67 : North American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
• Table 68 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
• Table 69 : Latin American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
• Table 70 : European Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
• Table 71 : European Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
• Table 72 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
• Table 73 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country/Region, Through 2028
• Table 74 : RoW Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
• Table 75 : Global Market for Viral Vector and Plasmid DNA Technologies, by Region, Through 2028
• Table 76 : North American Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
• Table 77 : North American Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
• Table 78 : Latin American Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
• Table 79 : Latin American Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
• Table 80 : European Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
• Table 81 : European Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
• Table 82 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
• Table 83 : Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
• Table 84 : RoW Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
• Table 85 : ESG Rankings of Major Companies, 2024*
• Table 86 : Lonza: ESG Performance
• Table 87 : Thermo Fisher Scientific Inc.: ESG Performance
• Table 88 : Acronyms Used in This Report
• Table 89 : Agilent Technologies Inc.: Company Snapshot
• Table 90 : Agilent Technologies Inc.: Financial Performance, FY 2021 and 2022
• Table 91 : Agilent Technologies Inc.: Product Portfolio
• Table 92 : Agilent Technologies Inc.: News/Key Developments, 2023
• Table 93 : Bluebird Bio Inc.: Company Snapshot
• Table 94 : Bluebird Bio Inc.: Financial Performance, FY 2021 and 2022
• Table 95 : Bluebird Bio Inc.: Product Portfolio
• Table 96 : Bluebird Bio Inc.: Key News/Developments, 2022
• Table 97 : Catalent Inc.: Company Snapshot
• Table 98 : Catalent Inc.: Financial Performance, FY 2021 and 2022
• Table 99 : Catalent Inc.: Product Portfolio
• Table 100 : Catalent Inc.: Key News/Developments, 2021-2024
• Table 101 : Danaher Corp.: Company Snapshot
• Table 102 : Danaher Corp.: Financial Performance, FY 2021 and 2022
• Table 103 : Danaher Corp.: Product Portfolio
• Table 104 : Danaher Corp.: News/Key Developments, 2022
• Table 105 : Fujifilm Holdings Corp.: Company Snapshot
• Table 106 : Fujifilm Holdings Corp.: Financial Performance, FY 2021 and 2022
• Table 107 : Fujifilm Holdings Corp.: Product Portfolio
• Table 108 : Fujifilm Holdings Corp.: News/Key Developments, 2022
• Table 109 : GenScript: Company Snapshot
• Table 110 : GenScript: Financial Performance, FY 2021 and 2022
• Table 111 : GenScript: Product Portfolio
• Table 112 : GenScript: News/Key Developments, 2023
• Table 113 : Gilead Sciences Inc.: Company Snapshot
• Table 114 : Gilead Sciences Inc.: Financial Performance, FY 2021 and 2022
• Table 115 : Gilead Sciences Inc.: Product Portfolio
• Table 116 : Gilead Sciences Inc.: News/Key Developments, FY 2021-2022
• Table 117 : Lonza: Company Snapshot
• Table 118 : Lonza: Financial Performance, FY 2021 and 2022
• Table 119 : Lonza: Product Portfolio
• Table 120 : Lonza: News/Key Developments, FY 2022
• Table 121 : Novartis AG: Company Snapshot
• Table 122 : Novartis AG: Financial Performance, FY 2021 and 2022
• Table 123 : Novartis AG: Product Portfolio
• Table 124 : Novartis AG: News/Key Developments, FY 2022
• Table 125 : Oxford Biomedica Plc: Company Snapshot
• Table 126 : Oxford Biomedica Plc: Financial Performance, FY 2021 and 2022
• Table 127 : Oxford Biomedica Plc: Product Portfolio
• Table 128 : Oxford Biomedica Plc: News/Key Developments, FY 2022
• Table 129 : PlasmidFactory GmbH: Company Snapshot
• Table 130 : PlasmidFactory GmbH: Product Portfolio
• Table 131 : Regenxbio Inc.: Company Snapshot
• Table 132 : Regenxbio Inc: Financial Performance, FY 2021 and 2022
• Table 133 : Regenxbio Inc: Product Portfolio
• Table 134 : Regenxbio Inc.: News/Key Developments, FY 2022
• Table 135 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 136 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2021 and 2022
• Table 137 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 138 : VGXI Inc.: Company Snapshot
• Table 139 : VGXI Inc.: Product Portfolio

List of Figures

• Summary Figure A : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, 2020-2028
• Summary Figure B : Global Market Shares of Viral Vector and Plasmid DNA Technologies, by Product Type, 2022
• Figure 1 : Viral Vector and Plasmid DNA Technologies: Market Dynamics
• Figure 2 : Approved Cell and Gene Therapy Product Count, 2003 to the Present
• Figure 3 : Emerging Trends/Technologies in Viral Vector and Plasmid DNA Technologies
• Figure 4 : Global Company Market Shares of Viral Vector and Plasmid DNA Technologies, 2022
• Figure 5 : Global Company Market Shares of Viral Vectors, 2022
• Figure 6 : Global Company Market Shares of Plasmid DNA, 2022
• Figure 7 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2022
• Figure 8 : Agilent Technologies Inc.: Revenue Share, by Region, FY 2022
• Figure 9 : Catalent Inc.: Revenue Share, by Business Unit, FY 2022
• Figure 10 : Catalent Inc.: Revenue Share, by Country/Region, FY 2022
• Figure 11 : Danaher Corp.: Revenue Share, by Business Unit, FY 2022
• Figure 12 : Danaher Corp.: Revenue Share, by Country/Region, FY 2022
• Figure 13 : Fujifilm Holdings Corp.: Revenue Share, by Business Unit, FY 2022
• Figure 14 : Fujifilm Holdings Corp.: Revenue Share, by Country/Region, FY 2022
• Figure 15 : GenScript: Revenue Share, by Business Unit, FY 2022
• Figure 16 : GenScript: Revenue Share, by Country/Region, FY 2022
• Figure 17 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2022
• Figure 18 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2022
• Figure 19 : Lonza: Revenue Share, by Business Unit, FY 2022
• Figure 20 : Lonza: Revenue Share, by Country/Region, FY 2022
• Figure 21 : Novartis AG: Revenue Share, by Business Unit, FY 2022
• Figure 22 : Novartis AG: Revenue Share, by Country/Region, FY 2022
• Figure 23 : Oxford Biomedica Plc: Revenue Share, by Business Unit, FY 2022
• Figure 24 : Oxford Biomedica Plc: Revenue Share, by Country/Region, FY 2022
• Figure 25 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2022
• Figure 26 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2022

The global market for viral vector and plasmid DNA technologies is expected to grow from $2.9 billion in 2023 to $7.1 billion by the end of 2028, at a compound annual growth rate (CAGR) of 19.7% from 2023 through 2028.

The global market for viral vector technology is expected to grow from $1.8 billion in 2023 to $4.5 billion by the end of 2028, at a CAGR of 20.7% from 2023 through 2028.

The global market for plasmid DNA technology is expected to grow from $1.1 billion in 2023 to $2.6 billion by the end of 2028, at a CAGR of 17.9% from 2023 through 2028.

Report Scope:

The report provides a comprehensive summary of the viral vector and plasmid DNA technologies market focusing cell and gene therapies, along with detailed competitive landscape and profiles of key market players that include revenue, product portfolios and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges, and opportunities. This research study discusses historical, current, and potential market size. The report will enable market players and new entrants to make informed decisions about the production and licensing of goods and services. Organizations, distributors, and exporters should find the information about market development and trends useful. The study segments the market on the basis of product type, applications, and end use. Geographical market analysis is provided for all the major segments. The report offers country-level analysis of markets to provide a better understanding of the major segments.

The market is divided into segments and by application/industry as follows:

By product type:

Viral vector.

Plasmid DNA.

By application:

Cancer.

Genetic disorders.

Infectious diseases.

Cardiovascular diseases.

Other diseases.

By end-user:

Research institutes.

Pharmaceutical and biopharmaceutical companies.

Each area is covered in detail, identifying current products in the market in the base year (2022), measuring the current market size and identifying current and potential market drivers, forecasting for 2028, assessing current and potential competitors, and identifying current competitor market shares for 2022.

Report Includes:

• 93 data tables and 47 additional tables
• An overview of the global market for viral vector and plasmid DNA
• Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Evaluation of the current market size and revenue growth prospects for viral vector and plasmid DNA, along with a market share analysis by product type, application and geographic region
• A look at the innovations, technological advances, and product launches from leading companies
• Analysis of the industry's regulatory framework and policies, and its product pipeline
• Discussion of ESG challenges and ESG practices
• Analysis of the key companies' market shares, proprietary technologies, strategic alliances and other market strategies, and patents
• Profiles of the leading players in the industry

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Viral Technology
• Cell and Gene Therapy

Chapter 3 Market Dynamics

• Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges

Chapter 4 Emerging Technologies and Developments

• Overview
• AI in Viral Vector Production
• Doggy Bone DNA
• FRAGment Recycler: A New Technology for Plasmid DNA Synthesis
• Patents
• Patent Holdings by Manufacturer
• Clinical Trials
• Selected Clinical Trials of Viral Vectors and Plasmid DNA Technologies

Chapter 5 Global Market for Viral Vector and Plasmid DNA Technologies

• Segmentation Breakdown
• Market Breakdown by Product Type
• Market Breakdown by End User
• Research Institutes
• Pharmaceutical and Biopharmaceutical Companies
• Market Breakdown by Application
• Cancer
• Genetic Disorders
• Infectious Diseases
• Cardiovascular Diseases
• Other Diseases
• Geographic Breakdown
• Market Breakdown by Region
• North America
• Latin America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 6 Competitive Intelligence

• Industry Scenario
• Company Shares
• Competitive Landscape among Companies
• Competitive Landscape in Viral Vectors
• Competitive Landscape in Plasmid DNA

Chapter 7 Sustainability in the Market for Viral Vector and Plasmid DNA Technologies: An ESG Perspective

• Introduction
• Environmental Factors
• Social Factors
• Governance Factors
• ESG Performance among Major Companies
• ESG Performance of Select Companies
• Lonza: ESG Performance
• Thermo Fisher Scientific: ESG Performance
• Conclusion

Chapter 8 Appendix

• Research Methodology
• Acronyms
• References
• Company Profiles
• AGILENT TECHNOLOGIES INC.
• BLUEBIRD BIO INC.
• CATALENT INC.
• DANAHER CORP.
• FUJIFILM HOLDINGS CORP.
• GENSCRIPT
• GILEAD SCIENCES INC.
• LONZA
• NOVARTIS AG
• OXFORD BIOMEDICA PLC
• PLASMIDFACTORY GMBH
• REGENXBIO INC.
• THERMO FISHER SCIENTIFIC INC.
• VGXI INC.